ProKidney Corp. Class A Ordinary Shares PROK
HEALTHCARE · BIOTECHNOLOGYi
Market dataready · fetched 2026-11-13T18:54:19.637Z
Delta surfaceAlpaca · derived absolute-delta buckets · 2027-01-15
Calculation methodologyOptions historyIV: ThetaData historical Greeks, equal-weight mean of call/put 50-delta IV across the next four listed Friday-cycle expirations, including holiday shifts verified against ThetaData’s market calendar. Missing inputs leave gaps. Skew: equal-weight mean of put minus call IV across those four expirations. IV-implied move history: mean of each expiration’s average call/put IV multiplied by the square root of remaining calendar days divided by 365.25; percentage of spot, not a quoted straddle premium.
History dataPriceAlpaca · sip · 2026-11-13T18:54:10.870678033Z
FundamentalsAlpha Vantage · ready · quarter 2026-06-30 · fetched 2026-11-13T18:50:56.032795+00:00
ProKidney Corp. Class A Ordinary Shares options
Table
| Delta | Calls | Puts | ||||
|---|---|---|---|---|---|---|
| Pseudo strike | IV | B/E move | Pseudo strike | IV | B/E move | |
| 20Δ | ||||||
| 25Δ | ||||||
| 30Δ | ||||||
| 35Δ | 3.89 | 303.7% | 286.2% | |||
| 40Δ | 3.29 | 294.2% | 231.6% | 1.11 | 131.6% | 20.2% |
| 45Δ | 2.68 | 284.7% | 176.9% | 1.23 | 142.1% | 18.5% |
| 50Δ | 2.07 | 275.2% | 122.3% | 1.35 | 152.6% | 16.8% |
| 55Δ | 1.83 | 283.4% | 104.1% | 1.47 | 163.1% | 15.1% |
| 60Δ | 1.64 | 294.1% | 90.9% | |||
| 65Δ | 1.45 | 304.7% | 77.7% | |||
| 70Δ | 1.26 | 315.3% | 64.5% | |||
| 75Δ | 1.06 | 326.0% | 51.4% | |||
| 80Δ | ||||||
20Δ
- Pseudo strike
- IV
- B/E move
- Pseudo strike
- IV
- B/E move
25Δ
- Pseudo strike
- IV
- B/E move
- Pseudo strike
- IV
- B/E move
30Δ
- Pseudo strike
- IV
- B/E move
- Pseudo strike
- IV
- B/E move
35Δ
- Pseudo strike
- 3.89
- IV
- 303.7%
- B/E move
- 286.2%
- Pseudo strike
- IV
- B/E move
40Δ
- Pseudo strike
- 3.29
- IV
- 294.2%
- B/E move
- 231.6%
- Pseudo strike
- 1.11
- IV
- 131.6%
- B/E move
- 20.2%
45Δ
- Pseudo strike
- 2.68
- IV
- 284.7%
- B/E move
- 176.9%
- Pseudo strike
- 1.23
- IV
- 142.1%
- B/E move
- 18.5%
50Δ
- Pseudo strike
- 2.07
- IV
- 275.2%
- B/E move
- 122.3%
- Pseudo strike
- 1.35
- IV
- 152.6%
- B/E move
- 16.8%
55Δ
- Pseudo strike
- 1.83
- IV
- 283.4%
- B/E move
- 104.1%
- Pseudo strike
- 1.47
- IV
- 163.1%
- B/E move
- 15.1%
60Δ
- Pseudo strike
- 1.64
- IV
- 294.1%
- B/E move
- 90.9%
- Pseudo strike
- IV
- B/E move
65Δ
- Pseudo strike
- 1.45
- IV
- 304.7%
- B/E move
- 77.7%
- Pseudo strike
- IV
- B/E move
70Δ
- Pseudo strike
- 1.26
- IV
- 315.3%
- B/E move
- 64.5%
- Pseudo strike
- IV
- B/E move
75Δ
- Pseudo strike
- 1.06
- IV
- 326.0%
- B/E move
- 51.4%
- Pseudo strike
- IV
- B/E move
80Δ
- Pseudo strike
- IV
- B/E move
- Pseudo strike
- IV
- B/E move
Options history
Table
| Date | IV (%) |
|---|---|
| 250.59% | |
| 255.98% |
Biotechnology
PRQR
ProQR Therapeutics NV, a biopharmaceutical company, is dedicated to the discovery and development of RNA-based therapies for the treatment of genetic disorders. The company is…
More →PRTA
Description unavailable
More →PTCT
PTC Therapeutics, Inc., a biopharmaceutical company, focuses on the discovery, development, and commercialization of drugs for patients with rare disorders. The company is…
More →PTGX
Protagonist Therapeutics, Inc., a clinical-stage biopharmaceutical company, discovers and develops peptide-based therapeutic drugs to address unmet medical needs. The company is…
More →PVLA
Palvella Therapeutics, Inc. is an innovative biotechnology firm dedicated to developing transformative therapies for rare genetic disorders resulting from specific gene mutations.…
More →PYPD
PolyPid Ltd., an advanced stage biopharmaceutical company, develops, manufactures and markets products based on the Polymer Lipid Encapsulation Matrix (PLEX) platform to address…
More →